BULLISH ON AZNAstraZeneca's Q3 2024 earnings exceeded expectations, with a revenue increase of 18%, signaling healthy demand for its products, especially in oncology and rare diseases.
Technicals - Key Indicators:
RSI (Relative Strength Index): Currently at 41.08, indicating strong bullish momentum but not ye